Stockscreener 앱 받기
119.35
0.29%
0.35
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Strength seen in Kymera Therapeutics (KYMR): Can its 16.6% jump turn into more strength? - MSN
Is Kymera (KYMR) the Best Performing American Stock in June 2026? - Insider Monkey
Kymera jumps 17% on early enrollment completion in skin disease study - MSN
Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Warren Buffett, Ray Dalio, Scion Asset Management, Brevan Howard, Kymera Therapeutics Inc (KYMR), Sony Group Corp (SONY), and More - Insider Monkey
(KYMR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Kymera Therapeutics Insider Sold Shares Worth $5,950,000, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics(KYMR.US) Officer Sells US$5.95 Million in Common Stock - Moomoo
Form 4 Kymera Therapeutics Inc For: 7 July By Investing.com - Investing.com Nigeria
Kymera Therapeutics CEO Mainolfi sells $5.95m in stock By Investing.com - Investing.com India
Kymera Therapeutics CEO Mainolfi sells $5.95m in stock - Investing.com
Form 144 Kymera Therapeutics For: 7 July By Investing.com - Investing.com Nigeria
Kymera Therapeutics, Inc. Announces Appointment of Elizabeth Laws as Senior Vice President - marketscreener.com
Kymera hires ex-Sanofi executive to lead KT-621 development - Investing.com
Kymera hires ex-Sanofi executive to lead KT-621 development By Investing.com - Investing.com South Africa
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader - The Manila Times
Kymera Therapeutics Insider Sold Shares Worth $8,864,829, According to a Recent SEC Filing - Moomoo
KYMRKymera Therapeutics Inc Options - Finviz
Kymera Therapeutics: Why It May Be Time To Jump On The Bandwagon (Upgrade) (NASDAQ:KYMR) - Seeking Alpha
Kymera: Building Toward A Defining 2H26 Moment (NASDAQ:KYMR) - Seeking Alpha
Kymera Therapeutics (KYMR) Stock Gets Fair Value Bump After KT 621 Timeline Shift - Yahoo Finance
Kymera Therapeutics(KYMR.US) Officer Sells US$9.22 Million in Common Stock - Moomoo
How Accelerated KT-621 Trial, Index Additions, and New Chair Will Impact Kymera Therapeutics (KYMR) Investors - Yahoo Finance
Insider Sell: Noah Goodman Sells Shares of Kymera Therapeutics I - GuruFocus
Kymera Therapeutics director Bruce Booth sells $8.28m in shares By Investing.com - Investing.com Australia
Kymera Therapeutics director Bruce Booth sells $8.28m in shares - Investing.com
Form 4 Kymera Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Form 144 Kymera Therapeutics For: 2 July By Investing.com - Investing.com Canada
Kymera Therapeutics (KYMR) Is Up 16.7% After KT-621 Trial Acceleration And Index Additions Has The Bull Case Changed? - Sahm
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug - Yahoo Finance
KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline - Stocktwits
Kymera Therapeutics director sells $56.5m in shares - Investing.com UK
Form 4 Kymera Therapeutics Inc For: 30 June By Investing.com - Investing.com Nigeria
Kymera Therapeutics director sells $56.5m in shares By Investing.com - Investing.com South Africa
Kymera Therapeutics director Booth sells $3.42 million in KYMR shares - Investing.com
Kymera Therapeutics director Booth sells $3.42 million in KYMR shares By Investing.com - Investing.com India
Kymera Therapeutics(KYMR.US) Director Sells US$59.88 Million in Common Stock - Moomoo
BofA Securities Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $125 - Moomoo
BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $125 - Moomoo
KYMR Maintained by B of A Securities -- Price Target Raised to $125 - GuruFocus
KYMR Maintained by B. Riley Securities -- Price Target Raised to $155 - GuruFocus
Form 144 KYMERA THERAPEUTICS For: 29 June By Investing.com - Investing.com Nigeria
KYMR Maintained by Truist Securities -- Price Target Raised to $136 - GuruFocus
B. Riley Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $155 - Moomoo
Kymera Therapeutics, Inc.(NasdaqGM: KYMR) added to Russell 2000 Value Benchmark - marketscreener.com
Truist raises Kymera Therapeutics price target on AD timeline By Investing.com - Investing.com Canada
B. Riley Adjusts Kymera Therapeutics Price Target to $155 From $117, Maintains Buy Rating - marketscreener.com
2.64%
자본화:
|
볼륨(24시간):